Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer-Reference-Cited by-同舟云学术

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Published:2015-04 Issue:4 Volume:26 Page:804-811
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bendell J.,O'Reilly E.M.,Middleton M.R.,Chau I.,Hochster H.,Fielding A.,Burke W.,Burris H.

Funder

AstraZeneca

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/4/804/16699270/mdu581.pdf

Reference14 articles.

1. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair;Ashworth;J Clin Oncol,2008

2. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas;Goggins;Cancer Res,1996

3. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers;Fong;N Engl J Med,2009

4. Randomized trial of olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis by BRCA mutation status;Ledermann;Lancet Oncol,2014

5. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models;Donawho;Clin Cancer Res,2007

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma;BMC Medicine;2024-09-04

2. GPX4 Inhibition Enhances the Antitumor Effect of PARP Inhibitor on Homologous Recombination Proficient Ovarian Cancer Cells;Current Cancer Drug Targets;2024-08-26

3. DRSPRING: Graph convolutional network (GCN)-Based drug synergy prediction utilizing drug-induced gene expression profile;Computers in Biology and Medicine;2024-05

4. PARP inhibitors combined with radiotherapy: are we ready?;Frontiers in Pharmacology;2023-10-26

5. Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-07